Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights. (2018)

• Record Type: Journal Article
• Authors: Foukas, Periklis G.; Tsiodras, Sotirios; Economopoulou, Panagiota; Spathis, Aris; Mademli, Maria; Leventakos, Konstantinos; Psyrri, Amanda; Karakitsos, Petros; Panayiotides, Ioannis G.
• Is Part Of: IDCases. Volume 11(2017)
• Page Start: 101
• Page End: 103
• Publication Date: 2018
• Subjects: Human Herpesvirus 6 -- Nivolumab -- Immunotherapy -- Lung cancer; Communicable diseases -- Periodicals; Communicable Diseases -- Case Reports; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; 616.9
• DOI: 10.1016/j.idcr.2018.01.013
• Languages: English
• ISSNs: 2214-2509

Abstract

Abstract: The development of immune system modulating agents, such as immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. Nivolumab, a human monoclonal antibody against PD-1, has emerged as an efficient treatment for various malignancies, including non-small cell lung cancer (NSCLC); however, it is associated with important immune related side-effects, attributed to organ-specific inflammation, such as immune-mediated pneumonitis, a relatively uncommon, albeit potentially fatal adverse event. We herein present the unique case of severe interstitial pneumonitis with concomitant detection of Human Herpes Virus 6 (HHV-6) in a nivolumab treated patient with NSCLC. Potential pathogenetic mechanisms are discussed.